Axsome Therapeutics, Inc. $AXSM Shares Newly Bought by New York Life Investment Management LLC

New York Life Investment Management LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 5,903 shares of the company’s stock, valued at approximately $1,088,000.

A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $759,695,000. ABS Investment Management LLC acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $171,339,000. Bank of America Corp DE acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $110,756,000. First Trust Advisors LP lifted its position in shares of Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after buying an additional 534,066 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in shares of Axsome Therapeutics by 12.9% during the 3rd quarter. Pictet Asset Management Holding SA now owns 481,524 shares of the company’s stock valued at $88,789,000 after buying an additional 54,997 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling

In related news, COO Mark Jacobson sold 10,000 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $141.69 on Monday. The business has a 50 day simple moving average of $171.45 and a two-hundred day simple moving average of $196.75. Axsome Therapeutics, Inc. has a 12 month low of $123.00 and a 12 month high of $260.19. The stock has a market capitalization of $7.45 billion, a P/E ratio of -46.30 and a beta of 0.86. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.42 and a quick ratio of 1.34.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.38. The business had revenue of $259.69 million for the quarter, compared to the consensus estimate of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The business’s quarterly revenue was up 51.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.94) earnings per share. As a group, analysts predict that Axsome Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on AXSM shares. Royal Bank Of Canada dropped their price target on shares of Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 3rd. UBS Group reduced their price objective on shares of Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Piper Sandler reduced their price objective on shares of Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating for the company in a research report on Monday, October 26th. Needham & Company LLC increased their price objective on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Truist Financial lifted their target price on shares of Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $266.21.

Check Out Our Latest Stock Analysis on AXSM

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Read More

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.